全球中樞神經系統 (CNS) 治療市場規模、佔有率和成長分析：按疾病、藥物類別和分銷管道 - 產業預測 (2024-2031)

Global CNS Therapeutics Market Size, Share, Growth Analysis, By Disease, By Drug Class, By Distribution Channel - Industry Forecast 2024-2031

出版日期: 2024年03月20日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年，全球中樞神經系統（CNS）治療市場規模為1,282.9億美元，預測期內（2024-2031年）複合年成長率為6.30%，2023年將達到1,363.7億美元。預計將從美國成長2031 年為2,223.3 億美元至2,223.3 億美元。

全球中樞神經系統 (CNS) 治療市場位於醫療保健和製藥領域，其特點是不斷發展和充滿活力。該領域廣泛涵蓋神經和精神疾病的治療，受益於對中樞神經系統複雜性的深入了解和正在進行的研究工作。推動這一領域成長的主要因素包括人們對心理健康問題的認知不斷提高和人口老化，以及對中樞神經系統藥物的需求增加。製藥公司與研究機構之間的合作將進一步推動該領域的創新。技術和科學進步有望改善中樞神經系統疾病患者的生活品質，但監管障礙、定價和市場競爭等挑戰正迫使行業參與者採取戰略應對措施。

Biogen Inc.（US）
Otsuka Pharmaceutical Co. Ltd（Japan）
Eli Lilly and Company（US）
Merck & Co.（US）
AstraZeneca（UK）
Takeda Pharmaceutical Company Limited（Japan）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Johnson & Johnson Private Limited（US）
Pfizer Inc.（US）
GlaxoSmithKline PLC（UK）
Sanofi（France）
AbbVie Inc.（US）
Roche Holding AG（Switzerland）
Bristol-Myers Squibb（US）
Lundbeck A/S（Denmark）
Allergan PLC（Ireland）
Eisai Co., Ltd.（Japan）
UCB SA（Belgium）
Sunovion Pharmaceuticals Inc.（US）

簡介目錄

Product Code: SQMIG35H2239

Global CNS Therapeutics Market size was valued at USD 128.29 Billion in 2022 and is poised to grow from USD 136.37 Billion in 2023 to USD 222.33 Billion by 2031, at a CAGR of 6.30% during the forecast period (2024-2031).

The Global Central Nervous System (CNS) Therapeutics market, situated within the healthcare and pharmaceutical sector, is characterized by constant evolution and dynamism. Covering a broad spectrum of treatments for neurological and psychiatric disorders, this sector benefits from increasing insights into the intricacies of the central nervous system and ongoing research endeavors. Key factors driving its growth include heightened awareness of mental health issues and an aging population, expanding the demand for CNS therapeutics. Collaboration between pharmaceutical entities and research institutions further propels innovation in the field. While technological and scientific progress promises enhanced quality of life for those afflicted by CNS disorders, challenges such as regulatory hurdles, pricing dynamics, and market competition necessitate strategic responses from industry players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global CNS Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global CNS Therapeutics Market Segmental Analysis

The global CNS therapeutics market is segmented on the basis of Disease, Disease type, distribution channel, and region. Based on disease the market is segmented as Neurovascular Diseases, Trauma, Mental Health, Degenerative Disease, Infectious Diseases, Cancer, and Others. On the basis of disease type the market is segmented as Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Other Drug Classes. Based on distribution channel, it is segregated into Hospitals Pharmacies, Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global CNS Therapeutics Market

As the global population ages, there is a noticeable increase in the occurrence of neurological disorders such as Alzheimer's and Parkinson's disease. This shift in demographics escalates the need for treatments and therapies targeting the central nervous system (CNS), as the elderly are particularly vulnerable to these ailments.

Restraints in the Global CNS Therapeutics Market

The process of creating drugs and treatments for neurological and psychiatric disorders entails navigating through thorough clinical trials and regulatory obstacles. The stringent examination conducted by regulatory bodies often results in delays and heightened expenses in introducing new therapies to the market, impeding both innovation and the prompt availability of effective treatments for patients.

Market Trends of the Global CNS Therapeutics Market

Advancements in genetics and neuroimaging have facilitated a comprehensive comprehension of diverse individual characteristics in central nervous system (CNS) disorders. This progression entails customizing treatments according to a patient's distinct genetic composition, neurobiological traits, and therapeutic responsiveness, thereby enhancing the precision and efficacy of interventions while reducing negative repercussions. Personalized methodologies hold the promise of transforming the treatment paradigm for ailments such as Alzheimer's, depression, and schizophrenia, presenting a hopeful trajectory for enhancing patient outcomes within the CNS therapeutics sector.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global CNS (Central Nervous System) Therapeutics Market by Disease

Market Overview
Neurovascular Diseases
Trauma
Mental Health
Degenerative Disease
Infectious Diseases
Cancer
and Others

Global CNS (Central Nervous System) Therapeutics Market by Drug Class

Market Overview
Analgesics
Antidepressants
Anesthetics
Anti-Parkinson Drugs
Anti-Epileptics
and Other Drug Classes

Global CNS (Central Nervous System) Therapeutics Market by Distribution Channel

Market Overview
Hospitals Pharmacies
Retail Pharmacies

Global CNS (Central Nervous System) Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co. Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Private Limited (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sunovion Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments